Case Study
New Biology
First-in-class Ph1 trial informed by new biology
K Pro
Biomarker Identification
AI Biotech
Clinical Trial Optimization
Click to enlarge
OKN4395
a first-in-class EP2/EP4/DP1 triple inhibitor, now in Ph1a
Ph1 trial of first-in-class drug through identification of new biology; better understanding MoA, biomarker ID and optimized indication selection
PGE2/PGD2 biology is complex, with unclear receptor roles and limited understanding of DP1 in tumor immunity, making early biomarker and indication selection uncertain. K Pro mapped pathway crosstalk in weeks to enable first-in-human clinical trial design.
What K Pro did
Unlock new biology, validate in wet lab
EP2/EP4/DP1 triple inhibition confirmed
Define new biomarkers, validate in wet lab
Gene expression signatures predicting favorable responder profiles
Design Phase 1 trial strategy
Top 4 cancer indications ranked & optimized combination strategy
Impact
Faster path to clinic
Hypothesis generation & validation in weeks, not months
Improved trial success
Biomarkers embedded from the start
Stronger indication selection
Driven by predictive pathway biology
Share to:
